SummitTX Capital L.P. Has $2.38 Million Stake in Celcuity, Inc. $CELC

SummitTX Capital L.P. increased its stake in shares of Celcuity, Inc. (NASDAQ:CELC) by 54.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,812 shares of the company’s stock after purchasing an additional 7,363 shares during the quarter. SummitTX Capital L.P.’s holdings in Celcuity were worth $2,375,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. NEA Management Company LLC raised its position in Celcuity by 64.9% in the 4th quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock worth $352,637,000 after purchasing an additional 1,391,300 shares during the last quarter. Avoro Capital Advisors LLC bought a new position in Celcuity in the 4th quarter valued at $310,302,000. Soleus Capital Management L.P. boosted its position in Celcuity by 17.0% in the 2nd quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock valued at $40,208,000 after buying an additional 437,696 shares during the last quarter. Vanguard Group Inc. boosted its position in Celcuity by 10.7% in the 4th quarter. Vanguard Group Inc. now owns 2,279,433 shares of the company’s stock valued at $227,351,000 after buying an additional 220,386 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Celcuity by 126.6% in the 4th quarter. State Street Corp now owns 1,637,687 shares of the company’s stock valued at $163,343,000 after buying an additional 914,887 shares during the period. 63.33% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Macquarie Infrastructure set a $160.00 target price on Celcuity in a research report on Thursday, May 28th. Citigroup reiterated an “outperform” rating on shares of Celcuity in a research report on Wednesday, July 15th. Wells Fargo & Company dropped their price objective on Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a report on Wednesday, June 3rd. Leerink Partners set a $155.00 target price on shares of Celcuity in a research report on Tuesday, June 2nd. Finally, Stifel Nicolaus set a $150.00 target price on shares of Celcuity in a research note on Monday, May 4th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Celcuity currently has an average rating of “Moderate Buy” and an average target price of $155.18.

Celcuity Stock Performance

Shares of Celcuity stock opened at $82.46 on Wednesday. The firm has a fifty day moving average of $102.07 and a two-hundred day moving average of $110.07. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31. The stock has a market capitalization of $4.02 billion, a price-to-earnings ratio of -21.14 and a beta of 0.16. Celcuity, Inc. has a 52 week low of $34.30 and a 52 week high of $151.02.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.10. As a group, equities research analysts predict that Celcuity, Inc. will post -3.76 EPS for the current year.

Insider Transactions at Celcuity

In other Celcuity news, Director Richard E. Buller sold 9,000 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the transaction, the director owned 6,760 shares in the company, valued at approximately $949,509.60. This trade represents a 57.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the transaction, the director owned 65,000 shares of the company’s stock, valued at $9,144,200. The trade was a 27.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is currently owned by company insiders.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.